A Risk Sciences International news item posted on June 22, 2021 and last updated on June 30, 2021

Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics.

A recent study published by RSI’s Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski in the journal JGH Open: An open access journal of gastroenterology and hepatology, has shown that only ciprofloxacin displayed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals.

The research team concluded that further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis.

The paper is available by clicking here.

More RSI News

Norman Shippee joins RSI

February 28, 2017

RSI is pleased to announce that Norman Shippee recently joined the team as a Climate and Applications Specialist. Dr. Shippee earned his PhD at the…

Emma Hartnett receives Chauncey Starr Distinguished Young Risk Analyst Award

December 15, 2016

The Society for Risk Analysis (SRA) Council has awarded Dr. Hartnett the 2016 Chauncey Starr Distinguished Young Risk Analyst Award. The Chauncey Starr Distinguished Young…

Dr. Donald R. Mattison co-authors: Adult Utilization of Psychiatric Drugs

December 12, 2016

Because there is limited information available concerning the use of psychiatric drugs among the US adult population, Drs Moore and Mattison sought to characterize adult…

RSI launches game-changing climate app

June 30, 2016

RSI launched the Climate Change Hazards Information Portal (CCHIP).